iBio, Inc. Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2020, compared with fiscal 2019. The supplied metadata references “2019 Q4,” but the filing is a fiscal-year 2020 Form 10-K filed October 13, 2020.
Business Context
iBio is a biotechnology company and biologics contract development and manufacturing organization. Its FastPharming platform uses hydroponically grown plants to develop and manufacture proteins, vaccines and therapeutics. Operations comprise a CDMO segment and proprietary biologics development and licensing activities.
During the second half of fiscal 2020 and after year-end, management shifted its primary focus toward proprietary biologics, including COVID-19 vaccines and therapeutics. Key programs included IBIO-100 for fibrosis, IBIO-200 and IBIO-201 for COVID-19, and IBIO-400 for classical swine fever. All proprietary vaccine and therapeutic candidates remained in preclinical development at year-end.
Financial Metrics
| Metric | FY2020 | FY2019 | Change |
|---|---|---|---|
| Revenue | $1.638 million | $2.018 million | Down 19% |
| Operating loss | $14.003 million | $15.788 million | Improved $1.785 million |
| Consolidated net loss | $16.444 million | $17.597 million | Improved $1.153 million |
| Net loss available to iBio stockholders | $38.260 million | $17.853 million | Worsened due primarily to deemed dividends |
| Basic and diluted loss per share | $0.61 loss | $0.94 loss | Improved per share |
| Cash used in operating activities | $13.345 million | $13.975 million | Improved $0.630 million |
| Cash balance | $55.112 million | $4.421 million | Increased $50.691 million |
| Accumulated deficit | $150.420 million | $105.821 million | Increased $44.599 million |
Revenue from CC-Pharming was approximately $1.268 million, or 77% of total revenue, versus $1.848 million, or 92%, in fiscal 2019. Revenue included approximately $46,000 from the Lung Biotechnology agreement and approximately $325,000 from other third-party customers.
Research and development expense declined to $3.213 million from $5.474 million. General and administrative expense increased modestly to $12.428 million from $12.332 million. Interest expense increased to $2.466 million from $1.900 million, primarily due to the finance-lease accounting and related Bryan, Texas facility obligations.
At June 30, 2020, total assets were $94.189 million, total liabilities were $37.582 million and total equity was $56.607 million. Finance lease obligations totaled $32.308 million, and the PPP loan totaled $600,000. The filing does not identify conventional funded debt apart from the PPP loan and lease obligations.
Material Changes Versus the Prior Period
- Revenue decreased 19% because of the timing and completion of work under the CC-Pharming relationship.
- Operating expenses declined, primarily due to lower third-party R&D, R&D personnel and consulting costs.
- Net loss attributable to iBio stockholders included a $21.560 million deemed dividend arising from the down-round adjustment to Series A and Series B preferred stock conversion terms.
- The company raised substantial equity capital and received warrant-exercise proceeds. Fiscal 2020 financing activities provided $65.192 million, including $62.363 million from preferred and common stock sales, $6.330 million from warrant exercises and $600,000 from the PPP loan.
- Common shares outstanding increased from approximately 20.2 million at June 30, 2019 to approximately 140.1 million at June 30, 2020, creating significant dilution. Approximately 180.3 million shares were outstanding as of October 8, 2020.
- Adoption of ASC 842 resulted in recognition of finance lease right-of-use assets of $27.616 million and related lease liabilities.
- The company revised previously reported March 31, 2020 financial information for an omitted stock issuance and identified a material weakness in internal control over financial reporting related to recording equity transactions on the settlement date instead of the trade date.
Guidance, Outlook, Risks and Unusual Items
Management stated that cash and marketable securities exceeded $83 million as of October 8, 2020 and expected available cash to support current activities through fiscal 2022. Management also stated that additional capital would be needed to fully execute its business and development plans, and that future equity financing could materially dilute shareholders.
The company expects continued operating losses and negative operating cash flow. It has not commercialized a proprietary vaccine or therapeutic and expects significant additional spending for preclinical work, clinical development, regulatory approval, manufacturing scale-up and personnel.
- COVID-19 caused reduced CDMO capacity and a three-day facility shutdown in April 2020 for cleaning after an employee infection. Future effects on operations and liquidity remained uncertain.
- The $600,000 PPP loan may be forgiven only if applicable SBA requirements are satisfied and forgiveness is approved.
- IBIO-201 was selected after year-end as the lead COVID-19 vaccine candidate based on preclinical results; the filing provides no assurance of clinical success or regulatory approval.
- The company relies heavily on a concentrated customer base, particularly CC-Pharming, and on collaborators, licensors, suppliers, CROs and third-party manufacturers.
- The Bryan, Texas facility is subject to a 34-year finance lease expiring in 2050, with annual base rent of approximately $2.1 million plus potential percentage rent and other costs.
- iBio is involved in continuing litigation with Fraunhofer. Several claims survived summary judgment, and trial was scheduled for March 1–5, 2021; the company could not predict the outcome.
- The company previously received NYSE American listing deficiency notices but reported regaining compliance by October 1, 2020 through the market-capitalization exemption.
- There is no independent auditor attestation on internal control effectiveness because iBio qualifies as a smaller reporting company.
Investor Verification Checklist
- Verify the timing, amount and terms of post-year-end equity issuances, including the UBS sales agreement and subsequent dilution.
- Review liquidity relative to the stated fiscal 2022 runway, ongoing operating cash burn and anticipated development spending.
- Assess the concentration and collectability of revenue from CC-Pharming and the company’s approximately $2.6 million backlog.
- Review the material weakness remediation and the revised March 31, 2020 financial information.
- Evaluate finance-lease obligations, minimum rent commitments and related-party transactions with Eastern affiliates.
- Track clinical, regulatory and manufacturing milestones for IBIO-100, IBIO-200, IBIO-201 and IBIO-400; none was approved for marketing as of the filing.
- Monitor the Fraunhofer litigation, PPP-loan forgiveness status, NYSE American compliance and the company’s need for additional financing.